Related references
Note: Only part of the references are listed.Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA
Peipei Nie et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Coming soon to a journal near you-The updated guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky
AUTOPHAGY (2014)
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins
J. Remon et al.
CANCER TREATMENT REVIEWS (2014)
Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells
Yunkyung Hong et al.
JOURNAL OF PINEAL RESEARCH (2014)
Resveratrol in the management of human cancer: how strong is the clinical evidence?
Andreas Gescher et al.
RESVERATROL AND HEALTH (2013)
Resveratrol-based combinatorial strategies for cancer management
Chandra K. Singh et al.
RESVERATROL AND HEALTH (2013)
Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
Hae Yun Nam et al.
AUTOPHAGY (2013)
Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway
Ai-Mei Gao et al.
CARCINOGENESIS (2013)
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
Ruey-Shyang Chen et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2013)
Expression of human ABCB5 confers resistance to taxanes and anthracyclines
Takaaki Kawanobe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance
Csilla Hegedues et al.
BIOCHEMICAL PHARMACOLOGY (2012)
The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
Nichelle C. Whitlock et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2012)
p53 signaling and autophagy in cancer A revolutionary strategy could be developed for cancer treatment
Xinbing Sui et al.
AUTOPHAGY (2011)
Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
D. Delmas et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
Roberta R. Alfieri et al.
MOLECULAR CANCER (2011)
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Ole Vang et al.
PLOS ONE (2011)
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
Lioubov G. Korotchkina et al.
AGING-US (2010)
Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression
Sin Ho Kweon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Cellular Senescence in the Development and Treatment of Cancer
Gabriele Saretzki
CURRENT PHARMACEUTICAL DESIGN (2010)
Transcription-independent p53 apoptosis: an alternative route to death
Daniel Speidel
TRENDS IN CELL BIOLOGY (2010)
Autophagy mediates the mitotic senescence transition
Andrew R. J. Young et al.
GENES & DEVELOPMENT (2009)
Can Epidermal Growth Factor Receptor-Fluorescent in Situ Hybridization Predict Clinical Benefit From Cetuximab Treatment in Patients With Non-Small-Cell Lung Cancer? IN REPLY
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
p53-dependent and p53-independent activation of autophagy by ARF
Wassirn M. Abida et al.
CANCER RESEARCH (2008)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
Atsuko Ogino et al.
CANCER RESEARCH (2007)
Coping with stress: multiple ways to activate p53
H. F. Horn et al.
ONCOGENE (2007)
Monoubiquitylation promotes mitochondrial p53 translocation
Natasha D. Marchenko et al.
EMBO JOURNAL (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
F Koizumi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma
NY Frank et al.
CANCER RESEARCH (2005)
Intracellular drug sequestration events associated with the emergence of multidrug resistance: A mechanistic review
M Duvvuri et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
AJ Barker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity
P Giannakakou et al.
ONCOGENE (2001)
Resistance mechanisms associated with altered intracellular distribution of anticancer agents
AK Larsen et al.
PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
